We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Epistem Announces Collaboration with GSK
News

Epistem Announces Collaboration with GSK

Epistem Announces Collaboration with GSK
News

Epistem Announces Collaboration with GSK

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Epistem Announces Collaboration with GSK"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Epistem plc, has announced a three year biomarker collaboration with GlaxoSmithKline in the field of fibrosis research.

The collaboration will focus on identifying key characteristics of diseased fibrotic tissue on which Epistem will apply its proprietary RNA-Amp™ technology to facilitate building an in depth understanding of the disease.

RNA-Amp™ is highly sensitive amplification technology which is able to provide gene expression information from small tissue samples and low of numbers of cells e.g. those obtained from the bulb of cells at the base of a single hair follicle, as well as laser captured micro dissected (LCM) samples.

Epistem is now the preferred partner of choice for a range of pharmaceutical companies providing gene expression biomarker information to support drug development programmes.

In addition to its amplification technology, Epistem brings its well respected cell and molecular biology expertise to the collaboration.

Epistem’s broad platform allows protein and gene expression biomarkers to be identified in important disease pathways at an early stage of pre-clinical validation for translation through to later stage clinical validation and patient stratification.

Advertisement